Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.64 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770201 | 0.90 | PTGDR2 (0.75) | PTGDR2PTGDR | |
| SCHEMBL3577547 | 0.89 | PTGDR2 (0.65) | PTGDR2PTGDRCASP6 | |
| SCHEMBL2774269 | 0.88 | PTGDR2 (0.51) | PTGDR2 | |
| SCHEMBL3577489 | 0.88 | PTGDR2 (0.60) | PTGDR2PTGDRTBXA2R | |
| SCHEMBL2769764 | 0.84 | PTGDR2 (0.57) | PTGDR2PTGDRCASP6 | |
| SCHEMBL3567663 | 0.84 | PTGDR2 (0.58) | PTGDR2PTGDR | |
| SCHEMBL2769602 | 0.83 | PTGDR2 (0.58) | PTGDR2 | |
| SCHEMBL3570130 | 0.82 | PTGDR2 (0.56) | PTGDR2PTGDRTBXA2R | |
| SCHEMBL2772862 | 0.81 | PTGDR2 (0.60) | PTGDR2PTGDR | |
| SCHEMBL3299837 | 0.79 | PTGDR2 (0.53) | PTGDR2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910357-B1 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LTD (GB) | 2010-04-14 | — | — | EP | disclosed |
| US-20090163534-A1 | Indolizine Derivatives | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163534-A1 | Indolizine Derivatives | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163534-A1 | Indolizine Derivatives | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-1910357-A2 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2006136859-A2 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163534-A1 | Indolizine Derivatives | HRH4, HRH2, NR1H2 | PTGDR2 363/4885PTGDR 270/4885CASP6 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.